You just read:

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

News provided by

Eli Lilly and Company

Jun 04, 2019, 21:01 ET